Taking everything into account, CYTK scores 2 out of 10 in our fundamental rating. CYTK was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. CYTK is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year CYTK has reported negative net income.
CYTK had a negative operating cash flow in the past year.
In the past 5 years CYTK always reported negative net income.
CYTK had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a Return On Assets value of -52.34%, CYTK perfoms like the industry average, outperforming 47.81% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-52.34%
ROE	N/A
ROIC	N/A

ROA(3y)-48.08%

ROA(5y)-38.73%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CYTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYTK has been increased compared to 1 year ago.
CYTK has more shares outstanding than it did 5 years ago.
CYTK has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.34, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
CYTK's Altman-Z score of -1.34 is in line compared to the rest of the industry. CYTK outperforms 54.10% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.34

ROIC/WACCN/A

WACC8.6%

2.3 Liquidity

A Current Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
The Current ratio of CYTK (6.88) is better than 69.33% of its industry peers.
A Quick Ratio of 6.88 indicates that CYTK has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.88, CYTK is doing good in the industry, outperforming 69.52% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.88
Quick Ratio	6.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CYTK have decreased strongly by -17.47% in the last year.
Looking at the last year, CYTK shows a very strong growth in Revenue. The Revenue has grown by 2609.26%.
The Revenue has been decreasing by -7.24% on average over the past years.

EPS 1Y (TTM)-17.47%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-87.5%

Revenue 1Y (TTM)2609.26%

Revenue growth 3Y-35.98%

Revenue growth 5Y-7.24%

Sales Q2Q%318.14%

3.2 Future

Based on estimates for the next years, CYTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.23% on average per year.
The Revenue is expected to grow by 235.38% on average over the next years. This is a very strong growth

EPS Next Y-23.98%

EPS Next 2Y-6.1%

EPS Next 3Y6.51%

EPS Next 5Y16.23%

Revenue Next Year2369.09%

Revenue Next 2Y564.95%

Revenue Next 3Y398.01%

Revenue Next 5Y235.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.